Sex differences in the effectiveness and tolerability of dolutegravir plus rilpivirine as a switch strategy in people living with HIV.
Luis Ramos-RupertoMaria Del Mar Arcos-RuedaRosa de Miguel-BuckleyCarmen Busca-ArenzanaRafael MicanRocío MontejanoAna Delgado-HierroMaría Luisa García MontesMaría Eulalia ValenciaLucía SerranoJosé Ramon ArribasJuan GonzálezJose Ignacio BernardinoLuz Martín-CarboneroPublished in: HIV medicine (2024)
DTG + RPV exhibited good and similar virological effectiveness in women and men in real-world settings. However, poorer tolerability and more treatment interruptions were observed in women.
Keyphrases
- polycystic ovary syndrome
- hiv infected patients
- randomized controlled trial
- systematic review
- open label
- antiretroviral therapy
- pregnancy outcomes
- cervical cancer screening
- breast cancer risk
- hiv infected
- double blind
- pregnant women
- insulin resistance
- clinical trial
- metabolic syndrome
- placebo controlled
- type diabetes
- adipose tissue